Findings: 🧠Response #biomarkers are needed for successful #NeuroOncology #immunotherapy trials 🧠Multiple molecular, cellular & radiologic approaches have shown promise 🧠Validation is needed before these biomarkers can be used to inform clinical trials bit.ly/3Iyxox6

This study provides regional insight into the molecular landscape of #meningiomas. It found while routine molecular profiling adds value to classification and prognostication, broader implementation may be limited by cost and panel coverage constraints. bit.ly/3Iuq71e

Read the new review in #NeuroOncology Advances focusing on recent advances and highlighting the #epidemiological, #pathological, #molecular/genetic, and clinical characteristics of #SpinalMeningiomas. academic.oup.com/noa/article/...

In our new special edition, #Immunotherapy for #BrainTumors, Alexander P Landry, Gavin P Dunn, and Michael Lim provide an overview of the current state of neuro-oncologic immunotherapy as covered in the supplement. academic.oup.com/noa/article/...

This new review and analysis reveals that #meningiomas can significantly impact #CognitiveFunction, affecting various domains such as memory, executive function, attention, and language. Most of these domains seem to improve postoperatively. bit.ly/4nn0RJb

The new supplement on #Immunotherapy for #BrainTumors is now out in #NeuroOncologyAdvances, edited by Alex Landry, Michael Lim, and Gavin Dunn. Thank you to the authors, peer reviewers, manuscript editors, and Editor-In-Chief @gelarehzadeh.bsky.social. bit.ly/460ahEQ

New Genetic Biomarker Flags Aggressive Brain Tumors @gelarehzadeh.bsky.social @mayocliniccancer.bsky.social @thelancetoncol.bsky.social #btsm #oncology www.onclive.com/view/new-gen...

Dr Linda Bi, Dr Ruchit Patel, Dr Chloe Gui, Dr Farshad Nassiri, and Dr Matija Snuderl joined the #Lancet #Oncology “In Conversation with” #podcast to discuss their new papers on #TERTexpression and TERT promoter mutations in #meningiomas. Listen now: www.thelancet.com/multimedia/p...

#ICOM & some of our members just published an article investigating the prevalence & prognostic association of #TERT expression in #meningiomas, with implications for diagnosis & treatment: bit.ly/4g8L0LZ @gelarehzadeh.bsky.social @justinzwang.bsky.social @felixehretmd.bsky.social @syip.bsky.social

What is the potential for #MolecularProfiling to refine surgical and #radiotherapy decision-making in #meningioma? Read the recent study in @NatureMedicine: go.nature.com/3GygVIj

#BAP1-altered #meningiomas represent a distinct and aggressive CNS tumor subtype associated with PRC dysregulation and recurrent 3p chromosome loss. These findings support the designation “meningioma, BAP1-altered.” Read full article in #NeuroOncology: bit.ly/3YWa1CN

Do you have clinical and research interests in #meningiomas, and want to find out more about becoming an #ICOM member? Contact us today: bit.ly/3HyhPoD

Collision tumors are rare. Among these, the metastasis of #melanoma into an intracranial #meningioma is particularly uncommon, with only 4 previously reported cases. This #CaseReport present the 5th documented case. bit.ly/3HOyZyr

This new study in Scientific Reports evaluates intracranial pressure in NF2-associated #meningiomas using perioperative #OpticNerveSheath diameter measurements. Read it now: go.nature.com/4oJWSI7

Have you read the new edition of our #ICOM newsletter? In it, you can read about the latest #meningioma-related events and articles from our members. adobe.ly/45yJe1R

Read this recent study in the JNS exploring potential correlations between the recurrence rate of #SphenoOrbital #meningiomas and the extent of resection of both the bony tumor portion and soft tumor portion. bit.ly/4mkxNBL

Read the new article “Postoperative #radiotherapy in subtotally resected recurrent WHO grade 1 #meningiomas with intermediate-/high-risk molecular profiles” in #NeuroOncology by authors including our #ICOM members: bit.ly/40wecpJ

The new edition of our #ICOM newsletter is now out! Read about the latest #meningioma-related events and articles from our members: adobe.ly/45yJe1R

A new study, showing that unidimensional tumor measurements and tumor volume assessments show a stronger association with overall survival than bidimensional measurements in recurrent non-benign #meningiomas, is now out in #NeuroOncology Advances: bit.ly/4l0xrPx

Read the Molecular Tumor Board Case Report in #NeuroOncologyAdvances on ‘Somatic SMARCB1 mutation in #SpinalMeningioma represents branched evolution in a patient with multiple sporadic #meningiomas’ now: bit.ly/41fTPx9

Our organization is truly #global, with #members from across Canada, the USA, Italy, Germany, the UK, Australia, Denmark, Hong Kong, Ireland, and Brazil. To learn more about #membership, click here: bit.ly/44xM7kG

Photos from the 2025 #BrainTumor Epidemiology Consortium (#BTEC) meeting at Duke University, including and Invited Speaker Panel of Quinn Ostrom, PhD (Duke); Priya Kumthekar, MD (Northwestern); Priscilla Brastianos, MD (Harvard); and John de Groot, MD (UCSF).

#ICOM was featured in the Mayo Clinic’s new article: “Launched in 2016, ICOM has 52 institutions working together to better understand treatment options, #meningioma biology that can guide management, and the most up-to-date indications for treatment.” www.mayoclinic.org/medical-prof...

#Meningiomas comprise 40% of all CNS neoplasms, with peak prevalence occurring in the 5th & 6th decades of life. Presenting symptoms vary between patients and are location-dependent, but new-onset seizures bring a subset of patients to clinical attention. bit.ly/46pC02j

Clara Lopez recently presented her research findings on "Exploring the Hormonal Influence and Sex-Specific Effects of Drug Metabolism in #Meningothelial and #AtypicalMeningioma” at the Department of Anaesthesia and Surgery's Biomedical Seminar Series in Wellington, New Zealand.

“Integrated proteomic and targeted Next Generation Sequencing reveal relevant heterogeneity in lower-grade meningioma and ANXA3 as a new target in NF2 mutated meningiomas” is now out in @eBioMedicine! Read full article here: bit.ly/4lE6G47

What are some topics of interest for us at #ICOM? These include (but are not limited to): - Current standard of #ClinicalCare - #Epidemiology - Quality of life and survivorship - #ClinicalTrial design - Molecular characterization Learn more here: buff.ly/4tsOyaG

This study, using retrospective data on 2,824 #meningiomas, highlights the potential for #MolecularProfiling to refine #surgical and #radiotherapy decision-making. Read more: go.nature.com/3GygVIj

Bruno Miguel Fernandes de Carvalho, MD PhD is a #Neurosurgery Graduate Hospital Assistant at the Neurosurgery Dept of Centro Hospitalar Universitário São João, Portugal. He specializes in #NeurosurgicalOncology, specifically glioma, metastasis, #meningioma & schwannoma surgery.

This research from a few years ago demonstrated that global patterns of DNA methylation may be informative for the selection of #chemotherapies against #meningiomas, and existing drugs may enhance radiation sensitivity in high-risk cases. Read now: bit.ly/4lGLL0l

Hot off the press! Read this great new article in @natcomms.nature.com “Distribution of copy number alterations and impact of chromosome arm call thresholds for #meningioma” from #ICOM member Dr. Wenya Linda Bi and her team! go.nature.com/44uEfyv

Meet our ICOM member Prof. C. Oliver Hanemann M.D., Ph.D., FRCP. He is the Associate Head of Research & Chair in Clinical #Neurobiology at @PlymUniMedicine, and leads the Brain Tumour Research Centre of Excellence. Research interests: #BrainTumours and #PeripheralNerveTumours

Interested in becoming a member of #ICOM? Our membership is based on shared clinical and research interests in #meningiomas, and we welcome new members from all disciplines and levels of training. Learn more: bit.ly/44xM7kG @gelarehzadeh.bsky.social

Findings: 1️⃣ Some patients achieved durable tumor control with nivolumab monotherapy although the PFS-6 primary endpoint was not met. 2️⃣ Most meningiomas exhibit low tumor mutational burden and density of infiltrating T cells. Read full article: bit.ly/44qXF8C

🚨New Research! “Targeting ANXA3 may offer a more #personalised approach to #treating #meningiomas in future, particularly for patients whose meningioma is a result of a mutation in a gene known as NF2” - Dr. Oliver Hanemann Read full article now: bit.ly/45HSkuY

Arie Perry, MD is a Professor of #Pathology and #NeurologicalSurgery UCSF, where he serves as Director of #Neuropathology and the Neuropathology Fellowship program. His interests focus on classification, grading and molecular characterization of adult and pediatric #BrainTumors.

“Challenges and opportunities in #meningiomas: recommendations from the International Consortium on Meningiomas” is a few years old but still relevant today. Read the #ICOM article in #NeuroOncology here: bit.ly/3TzURQp

This study “Radiographic prediction of meningioma grade by semantic and radiomic features” found a strong association between #imaging features of #meningioma and #histopathologic grade, with ready application to clinical management. Read the full article:https://bit.ly/45Sy3md

Since its founding in 2016, #ICOM has had a measurable impact on the #advancement of #meningioma research. To learn more about our organization, click here: bit.ly/41h5A6X

Read the review in #NeuroOncology Advances focusing on recent advances and highlighting the #epidemiological, #pathological, #molecular/genetic, and clinical characteristics of #SpinalMeningiomas. bit.ly/43GeR9K

Read the recent systematic review in #NeuroOncology Advances summarizing the outcomes measured and reported in #meningioma #ClinicalTrials. bit.ly/3F4hDwm

Looking for a comprehensive review of the current #clinical and #molecular landscape of #meningioma research? This book, edited by Gelareh Zadeh, Roland Goldbrunner, Boris Krischek, Farshad Nassiri, and with many #ICOM contributors, is a great resource! bit.ly/43pMETk

Today is #WorldBrainTumorDay—a day to raise awareness & advance research for those impacted by #BrainTumors. At #ICOM, we’re dedicated to improving treatment and patient outcomes through global #research snd #collaboration. Join us in advocating for continued research!

“Molecular signatures define BAP1-altered #meningioma as a distinct #CNStumor with deregulation of Polycomb repressive complex target genes” was recently released in #NeuroOncology - read the full article now! bit.ly/3YWa1CN

Want to learn more about #ICOM, #meningioma publications, and #membership? Head to our website: bit.ly/41h5A6X

#ICOM was recently highlighted by @gelarehzadeh.bsky.social in the @mayoclinic.org article “Using molecular information to guide #BrainTumor treatment” which discusses #meningioma research. Read it now: mayocl.in/4kMa38J

Read about a new study which findings suggest that 3D co-culture models offer an excellent system for studying the role of #ImmuneCells, specifically TAMs, in #meningioma progression. Read now in the Journal of Experimental & Clinical Cancer Research: bit.ly/3ZEF5XT

From our founding by @gelarehzadeh.bsky.social and @kenneth-aldape.bsky.social nine years ago, #ICOM has grown to over 115 members #worldwide. To learn more about our mission and our history, click play.

Quantitative #imaging analysis through #radiomics is a powerful technology to non-invasively assess molecular correlates and guide clinical decision-making. There has been growing interest in image-based phenotyping for #meningiomas. Read more: bit.ly/4kfv5fS

DOTATATE PET/MR represents a promising #ImagingBiomarker for response assessment in #meningiomas treated with #radiosurgery - this was the important finding from a recent study. Read about it now in #NeuroOncology: bit.ly/43qHvKW